stockrowargenex SE
ARGX Healthcare Biotechnology
argenex SE’s revenue for fiscal 2025 (year ended December 2025) was $4.2 billion, up 88.6% from fiscal 2024.
- Revenue
- +52.1%
- EPS
- +43.9%
- Free cash flow
- +537.5%
Quarter to September 2026, against a year earlier
Follow ARGX
Alert me
argenex SE (ARGX) Revenue
argenex SE's revenue for fiscal 2025 was $4.2B, up 88.6% from $2.3B in fiscal 2024. Over the twelve months to 30 September 2026 it was $5.9B. Over the past ten years it has ranged from $19.0M (fiscal 2016) to $4.2B (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 3 consecutive fiscal years. argenex SE ranks 5th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $4.2B | 88.63% |
| FY2024 | $2.3B | 77.52% |
| FY2023 | $1.3B | 184.91% |
| FY2022 | $445.3M | (17.45%) |
| FY2021 | $539.4M | 731.01% |
| FY2020 | $64.9M | (29.82%) |
| FY2019 | $92.5M | 167.93% |
| FY2018 | $34.5M | (25.97%) |
| FY2017 | $46.6M | 145.68% |
| FY2016 | $19.0M | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $1.8B | 13.55% |
| Jun 2026 | $1.5B | 17.44% |
| Mar 2026 | $1.3B | (0.76%) |
| Dec 2025 | $1.3B | 14.95% |
| 25 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| REGN Regeneron Pharmaceuticals, Inc. compare | $16.9B |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | $6.6B |
| INCY Incyte Corporation compare | $6.0B |
| ARGX argenex SE | $5.9B |
| GMAB Genmab A/S Sponsored ADR compare | $4.1B |
| RPRX Royalty Pharma PLC compare | $2.6B |
| MRNA Moderna, Inc. compare | $2.2B |
| RVMD Revolution Medicines, Inc. compare | $209.1M |
| ROIV Roivant Sciences Ltd. compare | $7.5M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on ARGX
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement